Abiraterone: a step forward in the treatment of prostate cancer
Trabectedin and pazopanib: an indirect comparison of their ability to treat LMS
When is the optimal time to use PARP inhibitors in prostate cancer patients?
Positive findings of the FOXTROT and RAPIDO trials
Improving patient outcomes using mHealth technologies